Company intelligence / Profile preview

Humedix

Seongnam-si, Gyeonggi-do, South Koreahumedix.com ↗

Ownership: Private
Development stage: Commercial

Overview

Humedix has a broad commercial portfolio in hyaluronic acid-based fillers, arthritis injectables, botulinum toxin type A (“Riztox”), PDRN-based regenerative therapies (“Livitalex”), medical devices (“Derma Shine”), and functional cosmetics. Its lead pipeline pharmaceutical program—GB‑5001 long‑acting donepezil injection—is in Phase 1 clinical trials targeting Alzheimer’s disease.

Therapeutic areas: DermatologyRheumatologyImmunologyNeurology
Modalities: Small moleculeBiologicBotulinum toxinPolymer-drug conjugate therapyMedical deviceCosmetic product formulations
Industry: Biotech

Drug pipeline

5 assets

Elravie Re2O

4 more assets in the full pipeline.

Request access →

Partnerships

G2GBio (platform/licensing partner on GB–5001)Korea Pharma Co.global biotechnology companies

Beyond the preview

Go deeper on Humedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Humedix.

Explore the full profile